Morepen Laboratories cash flow

Latest FY26

Cash from operations: ₹32.6cr+1.8% on FY25
Capital spending: ₹161cr−25.1% on FY25
Free cash flow: −₹128cr−₹182 cr in FY25
Cash from financing: ₹97.4cr−67.5% on FY25

₹ crore except per share

Tap a line for its trend	Last 12Mto Sep 2026	FY26Mar 2026	FY25Mar 2025	FY24Mar 2024	FY23Mar 2023	FY22 and earlierAlpha Plus

Changes in working capital
Adjustments to reconcile profit — non-cash items						FY22 and earlierEvery year the company has filed comes with Alpha Plus.
	—	36.4	29.0	33.5	27.9
	—	0.0	0.0	0.0	0.0
	—	16.4	8.3	3.7	2.0
	—	−0.0	0.1	0.2	0.0
	—	−0.8	0.0	0.0	0.0
	—	17.6	−51.4	−19.7	47.0
	—	−50.1	0.2	−61.7	−12.6
	—	−92.6	−131	−56.2	−50.4
	—	−1.1	0.2	0.0	0.0
	—	−24.7	0.0	0.0	0.0
	—	29.7	58.4	79.5	−142
	—	7.2	0.3	−2.8	−2.0
Cash from operating activities
	250	120	155	135	55.8
	—	−62.0	−85.9	−23.9	−130
	—	57.9	69.2	111	−74.6
	—	25.3	37.2	38.1	16.6
	—	32.6	32.1	73.4	−91.2
Cash from investing activities
	—	85.5	124	71.4	35.6
	—	75.0	90.2	10.0	10.4
	—	0.0	0.1	0.1	0.0
	—	0.0	83.7	1.3	0.0
	—	48.7	0.0	0.0	0.0
	—	43.3	23.6	0.7	0.5
	—	1.1	0.0	0.0	0.0
	—	30.6	0.0	0.0	0.0
	—	−123	−322	−83.3	−46.5
Cash from financing activities
	—	0.0	191	0.0	137
	—	132	50.4	3.8	7.0
	—	16.4	0.0	0.0	0.4
	—	5.7	−25.7	0.0	0.0
	—	16.4	8.3	3.7	2.0
	—	10.9	0.0	0.0	0.0
	—	15.0	41.4	5.1	1.8
	—	97.4	300	5.2	144
	—	6.6	10.4	−4.7	5.9
	—	6.6	10.4	−4.7	5.9
	—	—	—	16.9	21.7
Reference items
	276	126	174	159	79.5
	12.1%	7.0%	9.6%	9.4%	5.6%
	−128	−128	−182	−8.0	−137
	—	−29.0	−140	−7.8	—
	−₹2.33	−₹2.33	−₹3.32	−₹0.15	−₹2.50
	—	0.34×	0.27×	0.76×	−2.36×
	—	25.3	37.2	38.1	16.6
	—	16.4	8.3	3.7	2.0

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

alphave

MOREPENLAB₹125.58

Morepen Laboratories Limited

· Pharma & Health

₹ CrorePeersIOLCP INNOVACAP FDC ORCHPHARMA SENORES SANOFI GUJTHEM RPGLIFEMcap ₹6,881 Cr

View

In ₹ Crore except Per Share 12 Months Ending	FY23 31/03/2023	FY24 31/03/2024	FY25 31/03/2025	FY26 31/03/2026	Last 12M 30/09/2026
Adjustments to Reconcile Profit — Non-cash Items
+ Depreciation & Amortisation	27.9	33.5	29.0	36.4	—
+ Impairment Loss / (Reversal)	0.0	0.0	0.0	0.0	—
+ Finance Costs	2.0	3.7	8.3	16.4	—
+ Unrealised FX (Gain) / Loss	0.0	0.2	0.1	-0.0	—
+ Other Non-cash Items	0.0	0.0	0.0	-0.8	—
Changes in Working Capital
+ Inventories	47.0	-19.7	-51.4	17.6	—
+ Trade Receivables — Current	-12.6	-61.7	0.2	-50.1	—
+ Other Current Assets	-50.4	-56.2	-130.9	-92.6	—
+ Other Non-current Assets	0.0	0.0	0.2	-1.1	—
+ Trade Payables — Non-current	0.0	0.0	0.0	-24.7	—
+ Other Current Liabilities	-142.3	79.5	58.4	29.7	—
+ Provisions — Current	-2.0	-2.8	0.3	7.2	—
Cash from Operating Activities
Profit Before Tax (per I/S)	55.8	135.4	155.1	119.9	249.8
+ Total Adjustments (incl. Working Capital)	-130.4	-23.9	-85.9	-62.0	—
Cash from Operations (pre-tax)	-74.6	111.5	69.2	57.9	—
+ Income Taxes Paid	16.6	38.1	37.2	25.3	—
Cash from Operating Activities	-91.2	73.4	32.1	32.6	—
Cash from Investing Activities
+ Acq of Fixed Assets (Capex)	35.6	71.4	124.0	85.5	—
+ Acq of Intangible Assets	10.4	10.0	90.2	75.0	—
+ Disp of Fixed Assets	0.0	0.1	0.1	0.0	—
+ Acq of Investment Property	0.0	1.3	83.7	0.0	—
+ Disp of Investment Property	0.0	0.0	0.0	48.7	—
+ Acq of Other Long-term Assets	0.5	0.7	23.6	43.3	—
+ Disp of Other Long-term Assets	0.0	0.0	0.0	1.1	—
+ Disp of Subsidiaries / Businesses (net)	0.0	0.0	0.0	30.6	—
Cash from Investing Activities	-46.5	-83.3	-321.5	-123.4	—
Cash from Financing Activities
+ Proceeds from Issue of Shares	137.2	0.0	190.7	0.0	—
+ Proceeds from Borrowings	7.0	3.8	50.4	131.8	—
+ Repayment of Borrowings	0.4	0.0	0.0	16.4	—
+ Payment of Lease Liabilities	0.0	0.0	-25.7	5.7	—
+ Interest Paid	2.0	3.7	8.3	16.4	—
+ Dividends Paid	0.0	0.0	0.0	10.9	—
+ Other Inflows / (Outflows) — Financing	1.8	5.1	41.4	15.0	—
Cash from Financing Activities	143.5	5.2	299.9	97.4	—
Net Changes in Cash (pre-FX)	5.9	-4.7	10.4	6.6	—
Net Changes in Cash	5.9	-4.7	10.4	6.6	—
Closing Cash	21.7	16.9	—	—	—
Reference Items
EBITDA	79.5	158.6	174.1	125.6	276.4
EBITDA Margin %	5.61	9.38	9.61	6.96	12.09
Free Cash Flow (CFO − Capex)	-137.1	-8.0	-182.2	-127.9	-127.9
Free Cash Flow to Equity	—	-7.8	-140.1	-29.0	—
Free Cash Flow per Basic Share	-2.50	-0.15	-3.32	-2.33	-2.33
Cash Flow to Net Income	-2.36	0.76	0.27	0.34	—
Cash Paid for Taxes	16.6	38.1	37.2	25.3	—
Cash Paid for Interest	2.0	3.7	8.3	16.4	—

As filed, sign as filed: a payment tagged as a positive magnitude in the filing stays positive here, so read the label, not the sign. A line appears only when the company tagged that concept in at least one period shown — depth follows the filer, so a thin statement means a thin filing. Total Adjustments is the filer's own grand total of the reconciliation and spans BOTH the non-cash items and the working-capital block; Profit Before Tax plus it equals Cash from Operations (pre-tax). It can be reported when its components are not, so it is never a sum of the rows above it. No consensus estimates → no Est columns. Click any row to chart it.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.